Post-IPO Vitae gets Phase I BACE hit, advances new strategy
This article was originally published in Scrip
Executive Summary
Vitae Pharmaceuticals emerged from the quiet period following its initial public offering ready to advance its drug development strategy and with positive Phase I results for the beta secretase (BACE) inhibitor it's developing in collaboration with Boehringer Ingelheim for Alzheimer's disease.